Nutrition Sufficiency, Allergy Efficacy and Safety of Neocate Jr in Children With Food Protein Allergy

NCT ID: NCT05406141

Last Updated: 2022-06-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-30

Study Completion Date

2023-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to evaluate efficacy and safety of an amino acid-based formula Neocate Jr in children with food protein allergy, and to evaluate nutrition sufficiency of Neocate Jr in 1 to 10 years old children with food protein allergy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open, self-controlled multi-center clinical study. Target population is 1~10 years old children allergic to cow's milk and/or food protein, confirmed by pediatrician. The study plans to recruit about 50 subjects to have an intervention period of 4 weeks. Data will be collected at baseline, week 1, 2 and 4. The hypothesis is that the amino acid formula (Neocate Jr) is effective in relieving food protein allergy symptoms, and meanwhile supporting normal growth in children with food protein allergy. Efficacy parameters are the the improvement of food protein allergy symptoms (SCORAD score, serum IgE), growth and development index (weight, height, weight for height), and nutrition related labs (such as hemoglobin, total blood protein, albumin, pre-albumin).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Food Allergy in Children Cow Milk Allergy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

children with food protein allergy

Group Type EXPERIMENTAL

Amino acid formula (Neocate Jr)

Intervention Type DIETARY_SUPPLEMENT

Use Neocate Jr for 4 weeks, either as sole source of nutrition or oral nutritional supplement:

* Sole source of nutrition: as far as possible \>7 days, especially newly diagnosed allergy children
* Oral nutritional supplement (Neocate Jr ≥50% of daily total energy and the rest provided by food)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amino acid formula (Neocate Jr)

Use Neocate Jr for 4 weeks, either as sole source of nutrition or oral nutritional supplement:

* Sole source of nutrition: as far as possible \>7 days, especially newly diagnosed allergy children
* Oral nutritional supplement (Neocate Jr ≥50% of daily total energy and the rest provided by food)

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1~10 years old
* The children with cow's milk/food protein allergy confirmed by pediatrician including sequential feeding/newly diagnosed children, and children with Eosinophilic Esophagitis, Gastroesophageal reflux disease, Food Protein-Induced Enterocolitis Syndrome (clinical symptoms and signs, IgE, oral food challenge, etc.)
* Stable Vital Signs
* Written informed consent from the children's parents/guardian

Exclusion Criteria

* Allergic to any ingredient in the recipe
* GI function failure
* Complete obstruction of the digestive tract
* Intractable diarrhea
* Noncooperation of neurologic or mental diseases
* Disapproval of pediatricians
Minimum Eligible Age

1 Year

Maximum Eligible Age

10 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beijing Children's Hospital

OTHER

Sponsor Role collaborator

Children's Hospital of The Capital Institute of Pediatrics

OTHER

Sponsor Role collaborator

Chinese Academy of Medical Sciences

OTHER

Sponsor Role collaborator

Peking University Third Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zailing Li

Role: PRINCIPAL_INVESTIGATOR

Peking University Third Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peking University Third Hospital

Beijing, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zailing Li

Role: CONTACT

+8613810095709

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Zailing Li

Role: primary

+8613810095709

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

202107 V2.0

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.